Our team is developing octreotide capsules (conditionally trade named Mycapssa®) for the maintenance treatment of acromegaly in adults—a rare, serious chronic disease. Acromegaly is typically caused by a benign tumor of the pituitary gland that releases excess growth hormone (GH), leading to excess growth of certain parts of the body.
How Octreotide Capsules are Designed to Work
Octreotide capsules are designed to exhibit the effects of somatostatin, a naturally occurring hormone that reduces the production of GH by binding to receptors on specialized cells in the pituitary gland.
Because octreotide capsules were developed using our Transient Permeability Enhancer (TPE®) technology, they can be administered orally and absorbed into the bloodstream. This means octreotide capsules have the potential to serve as an alternative to the current standard-of-care injection therapy that is available for people living with acromegaly today. There are currently no approved oral formulations of octreotide.
The following scientific resources provide additional information about the potential of octreotide capsules for the maintenance treatment of acromegaly.
- Melmed S, al. “Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial.” The Journal of Clinical Endocrinology & Metabolism, Volume 100, Issue 4, 1 April 2015, Pages 1699–1708, https://doi.org/10.1210/jc.2014-4113
- Tuvia S, et. Al. “A Novel Suspension Formulation Enhances Intestinal Absorption of Macromolecules Via Transient and Reversible Transport Mechanisms.” Pharmaceutical Research, Volume 31, issue 8, 21 February 2014, Pages 2010–2021, https://doi.org/10.1007/s11095-014-1303-9
Octreotide capsules (conditionally trade named Mycapssa®) and any other drug candidate developed using our Transient Permeability Enhancer (TPE®) technology platform are investigational and have not been approved by the U.S. Food and Drug Administration, the European Medicines Agency or any other regulatory agency.